Description Results NMA

all cause mortality ∞ [NaN; ∞]

Withdrawals due to adverse effects 3.50 [0.77; 15.96]

Pro-arrhythmia NaN [NaN; NaN]

Atrial fibrillation recurrence 0.75 [0.54; 1.05]

all cause mortality NaN [NaN; NaN]

Pro-arrhythmia NaN [NaN; NaN]

Atrial fibrillation recurrence 0.81 [0.53; 1.24]

Disopyramide 500 mg/d (n=46)

vs.

palcebo (n=46)

open

Parallel groups

Sample size: 46/46

Primary endpoint:

FU duration: 12 months

Disopyramide 450 mg/d , (n=29)

vs.

placebo (n=25)

double blind

Parallel groups

Sample size: 29/25

Primary endpoint:

FU duration: 6 months

Disopyramide 450 mg/d , , (n=29)

vs.

placebo (n=28)

double blind

Parallel groups

Sample size: 29/28

Primary endpoint:

FU duration: 6 months

all cause mortality ∞ [NaN; ∞]

Withdrawals due to adverse effects 0.40 [0.14; 1.19]

Pro-arrhythmia 0.81 [0.05; 12.26]

Atrial fibrillation recurrence 0.73 [0.37; 1.44]

Disopyramide 750 mg/d (n=31)

vs.

propafenone 900 mg/d (n=25)

double blind

Parallel groups

Sample size: 31/25

Primary endpoint:

FU duration: 6 months